Please check your internet connection and try again.
# Walethmade bromide
## Overview
Walethmade bromide is an anticholinergic medication.
## Primary Indications
* Treatment of Parkinson's disease (especially drug-induced parkinsonism).
* Management of extrapyramidal symptoms of antipsychotic medications.
## Adult Dosing
* **Parkinsonism:** Typically initiated at 1 mg orally once or twice daily, may be increased gradually up to a maximum of 6 mg orally three times daily.
* **Drug-induced extrapyramidal symptoms:** Typically 1 mg to 2 mg orally, one to three times daily.
Dosing should be individualized based on patient response and tolerance.
## Pediatric Dosing
Information on pediatric use is not well-established. Use with caution and at the lowest effective dose.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution; dose reduction may be necessary.
* **Renal Impairment:** Use with caution; dose reduction may be necessary.
* Elderly patients may be more sensitive to anticholinergic effects; start with lower doses and titrate slowly.
## Contraindications
* Angle-closure glaucoma.
* Myasthenia gravis.
* Untreated narrow-angle glaucoma.
* Known hypersensitivity to walethmade bromide or its components.
* Pyloric or duodenal obstruction, cardiospasm, achalasia, etc., (conditions that obstruct gastrointestinal transit).
## Adverse Effects
**Common:**
* Dry mouth
* Constipation
* Blurred vision
* Drowsiness
* Confusion
* Urinary retention
* Tachycardia
**Less Common/Serious:**
* Cognitive impairment, especially in the elderly
* Hallucinations
* Increased intraocular pressure
* Heat prostration (in hot weather)
## Key Drug Interactions
* **Other Anticholinergics:** Additive anticholinergic effects.
* **CNS Depressants:** Increased CNS depression (e.g., alcohol, benzodiazepines, opioids).
* **Amantadine:** Increased risk of anticholinergic adverse effects.
* **MAO Inhibitors:** May potentiate anticholinergic effects.
* **Cisapride:** Decreased efficacy of cisapride.
* **Digoxin:** May decrease absorption of digoxin.
## Monitoring
* Monitor for signs and symptoms of anticholinergic toxicity (e.g., dry mouth, blurred vision, constipation, urinary retention, confusion, delirium).
* Assess for improvement in parkinsonian symptoms or extrapyramidal side effects.
* Regularly review medication for continued need and potential for dose reduction.
* Consider intraocular pressure if glaucoma is a concern.
## Clinical Pearls
* Administer with caution in patients with cardiovascular disease, prostatic hypertrophy, or hot weather exposure.
* Tolerance to anticholinergic effects may develop over time.
* May be taken with or without food. Taking with food may reduce gastrointestinal upset.
* Discontinuation should be gradual to prevent withdrawal symptoms or worsening of symptoms.
***
*This information is intended for healthcare professionals. Always consult the most current prescribing information and professional guidelines before making clinical decisions. Dosing and recommendations may vary based on patient-specific factors and local institutional protocols.*
